Advanced in Acute Lymphoblastic Leukemia (ALL)

Dr. Eneida R. Nemecek

Pediatric Hematology Oncology
University Professional Services
3181 Sw Sam Jackson Park Rd, 
Portland, OR 
Clinical Trials:Currently Recruiting for 1 Trial
23 Years of Experience
Advanced in Acute Lymphoblastic Leukemia (ALL)
University Professional Services
3181 Sw Sam Jackson Park Rd, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eneida Nemecek is a Pediatric Hematologist Oncology provider in Portland, Oregon. Dr. Nemecek has been practicing medicine for over 23 years and is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Graft Versus Host Disease (GvHD), Acute Lymphoblastic Leukemia (ALL), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 61 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 7 articles and participated in 4 clinical trials in the study of Acute Lymphoblastic Leukemia (ALL).

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in OR
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

BridgeSpan
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
View 1 Less Insurance Carrier -

Locations

UNIVERSITY PROFESSIONAL SERVICES
3181 Sw Sam Jackson Park Rd, Portland, OR 97239

Additional Areas of Focus

Dr. Nemecek has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 19, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: June 20, 2024
Intervention Type: Drug, Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2023
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug
Study Drugs: Rivogenlecleucel, Rimiducid
Study Phase: Phase 1/Phase 2
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Enrollment Status: Unknown
Publish Date: February 08, 2023
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501 T Cells, Rimiducid
Study Phase: Phase 1/Phase 2
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Enrollment Status: Completed
Publish Date: March 17, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Biological
Study Phase: Phase 2
View 8 Less Clinical Trials

61 Total Publications

Identification of Distinct Subtypes in Immune Tolerance after Hematopoietic Cell Transplantation Using the Prospective ABLE1.0 Pediatric Study Cohort.
Identification of Distinct Subtypes in Immune Tolerance after Hematopoietic Cell Transplantation Using the Prospective ABLE1.0 Pediatric Study Cohort.
Journal: Transplantation and cellular therapy
Published: April 07, 2025
Similar Doctors
Advanced in Acute Lymphoblastic Leukemia (ALL)
Dr. Adam J. Lamble
Pediatric Hematology Oncology
Advanced in Acute Lymphoblastic Leukemia (ALL)
Dr. Adam J. Lamble
Pediatric Hematology Oncology
3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (0.1 miles away)
503-494-8211
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adam Lamble is a Pediatric Hematologist Oncology provider in Portland, Oregon. Dr. Lamble is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Leukemia, Childhood Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Acute Lymphoblastic Leukemia (ALL)
Dr. Janice F. Olson
Pediatric Hematology Oncology
Advanced in Acute Lymphoblastic Leukemia (ALL)
Dr. Janice F. Olson
Pediatric Hematology Oncology
2801 N Gantenbein Ave, 
Portland, OR 
 (3.2 miles away)
503-276-9300
Languages Spoken:
English
See accepted insurances

Janice Olson is a Pediatric Hematologist Oncology provider in Portland, Oregon. Dr. Olson is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Hepatoblastoma, Reticulohistiocytoma, Histiocytosis, and Bone Marrow Aspiration.

Advanced in Acute Lymphoblastic Leukemia (ALL)
Dr. Linda C. Stork
Pediatric Hematology Oncology
Advanced in Acute Lymphoblastic Leukemia (ALL)
Dr. Linda C. Stork
Pediatric Hematology Oncology

University Professional Services

15700 Sw Greystone Ct, 
Beaverton, OR 
 (7.5 miles away)
503-494-3442
Languages Spoken:
English
See accepted insurances

Linda Stork is a Pediatric Hematologist Oncology provider in Beaverton, Oregon. Dr. Stork is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Infantile Neutropenia, Rhabdomyosarcoma, Hepatoblastoma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nemecek's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile